

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-40. (cancelled)

Claim 41 (new): An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

KVAELVHFL (SEQ ID NO:711); and

YLQLVFGIEV (SEQ ID NO:270).

Claim 42 (new): The peptide of claim 41, wherein said oligopeptide is KVAELVHFL (SEQ ID NO:711).

Claim 43 (new): The peptide of claim 41, wherein said oligopeptide is YLQLVFGIEV (SEQ ID NO:270).

Claim 44 (new): The peptide of claim 42, which is 11 amino acids in length.

Claim 45 (new): The peptide of claim 42, which is 10 amino acids in length.

Claim 46 (new): The peptide of claim 42, which is 9 amino acids in length.

Claim 47 (new): The peptide of claim 43, which is 11 amino acids in length.

Claim 48 (new): The peptide of claim 43, which is 10 amino acids in length.

Claim 49 (new): The peptide of claim 41, which is fused to a T helper peptide.

Claim 50 (new): The peptide of claim 41, which is fused to spacer or linker amino acids.

Claim 51 (new): The peptide of claim 41, which is fused to a carrier.

Claim 52 (new): The peptide of claim 41, which is linked to a lipid.

Claim 53 (new): A fusion protein comprising the peptide of claim 41.

Claim 54 (new): A homopolymer of the peptide of claim 41.

Claim 55 (new): A heteropolymer of the peptide of claim 41 and different peptides.

Claim 56 (new): A composition comprising the peptide of claim 41 and a carrier.

Claim 57 (new): A composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.

Claim 58 (new): A composition comprising the peptide of claim 41 and a liposome.

Claim 59 (new): A composition comprising the peptide of claim 41, and one or more different peptides.

Claim 60 (new): The composition of claim 59, wherein said peptides form a fusion protein.

Claim 61 (new): The composition of claim 59, which comprises a carrier.

Claim 62 (new): The composition of claim 59 further comprising a pharmaceutically acceptable carrier.

Claim 63 (new): The composition of claim 59, wherein said peptides are fused by spacer or linker amino acids.